The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ventre, K., & Randolph, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000181.pub3 · Cited by 312
RetractedMortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Bronchiolitis-Associated Hospitalizations Among US Children, 1980-1996
Shay, D. K. (1999) · JAMA · doi:10.1001/jama.282.15.1440 · Cited by 1,385
Johnsson, B., Löfås, S., & Lindquist, G. (1991) · Analytical Biochemistry · doi:10.1016/0003-2697(91)90424-r · Cited by 1,262
Chanock, R. M., Kim, H. W., Brandt, C., & Parrott, R. H. (1976) · Viral Infections of Humans · doi:10.1007/978-1-4613-3988-5_17 · Cited by 1,085
Johnson, S., Oliver, C., Prince, G. A., Hemming, V. G., Pfarr, D. S., Wang, S., Dormitzer, M., O'Grady, J., Koenig, S., Tamura, J. K., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514115 · Cited by 641
Self-citationHall, C. B., McBride, J. T., Walsh, E. E., Bell, D. M., Gala, C. L., Hildreth, S., Ten Eyck, L. G., & Hall, W. J. (1983) · New England Journal of Medicine · doi:10.1056/nejm198306163082403 · Cited by 550
(2019) · Canadian Family Practice Guidelines · doi:10.1891/9780826194985.0134 · Cited by 336
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
COMMITTEE ON INFECTIOUS DISEASES AND BRONCHIOLITIS GUIDELINES COMMITTEE, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., et al. (2014) · Pediatrics · doi:10.1542/peds.2014-1665 · Cited by 771
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Proof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555
Delgado, M. F., Coviello, S., Monsalvo, A. C., Melendi, G. A., Hernandez, J. Z., Batalle, J. P., Diaz, L., Trento, A., Chang, H.-Y., Mitzner, W., et al. (2009) · Nature Medicine · doi:10.1038/nm.1894 · Cited by 500
McLellan, J. S., Yang, Y., Graham, B. S., & Kwong, P. D. (2011) · Journal of Virology · doi:10.1128/jvi.00555-11 · Cited by 436
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
COMMITTEE ON INFECTIOUS DISEASES and BRONCHIOLITIS GUIDELINES COMMITTEE, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., et al. (2014) · Pediatrics · doi:10.1542/peds.2014-1666 · Cited by 386
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
Krarup, A., Truan, D., Furmanova-Hollenstein, P., Bogaert, L., Bouchier, P., Bisschop, I. J. M., Widjojoatmodjo, M. N., Zahn, R., Schuitemaker, H., McLellan, J. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9143 · Cited by 383
Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins
McLellan, J. S., Ray, W. C., & Peeples, M. E. (2013) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-38919-1_4 · Cited by 380
Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
Self-citationTargeted glycan degradation potentiates the anticancer immune response in vivo
Gray, M. A., Stanczak, M. A., Mantuano, N. R., Xiao, H., Pijnenborg, J. F. A., Malaker, S. A., Miller, C. L., Weidenbacher, P. A., Tanzo, J. T., Ahn, G., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0622-x · Cited by 362
The role of viruses in acute exacerbations of asthma
Jackson, D. J., & Johnston, S. L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.021 · Cited by 351
“In a rat model it had 50 to 100 times greater anti-RSV activity in the lower respiratory tract compared with palivizumab.(114) In a large phase 3 noninferiority study comparing motavizumab with palivizumab for RSV prevention in high-risk children, motavizumab demonstrated fewer RSV-induced hospitalizations and a reduc…”
BackgroundBiodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Tabrizi, M., Bornstein, G. G., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-009-9157-5 · Cited by 305
Swanson, K. A., Settembre, E. C., Shaw, C. A., Dey, A. K., Rappuoli, R., Mandl, C. W., Dormitzer, P. R., & Carfi, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106536108 · Cited by 285
The growth and potential of human antiviral monoclonal antibody therapeutics
Marasco, W. A., & Sui, J. (2007) · Nature Biotechnology · doi:10.1038/nbt1363 · Cited by 284
Rudicell, R. S., Kwon, Y. D., Ko, S.-Y., Pegu, A., Louder, M. K., Georgiev, I. S., Wu, X., Zhu, J., Boyington, J. C., Chen, X., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02213-14 · Cited by 282
Detalle, L., Stohr, T., Palomo, C., Piedra, P. A., Gilbert, B. E., Mas, V., Millar, A., Power, U. F., Stortelers, C., Allosery, K., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01802-15 · Cited by 279
Horton, H. M., Bernett, M. J., Pong, E., Peipp, M., Karki, S., Chu, S. Y., Richards, J. O., Vostiar, I., Joyce, P. F., Repp, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2268 · Cited by 272
Monoclonal antibody therapies against SARS-CoV-2
Focosi, D., McConnell, S., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 269
Designing antibodies as therapeutics
Carter, P. J., & Rajpal, A. (2022) · Cell · doi:10.1016/j.cell.2022.05.029 · Cited by 267
Sharma, V. K., Patapoff, T. W., Kabakoff, B., Pai, S., Hilario, E., Zhang, B., Li, C., Borisov, O., Kelley, R. F., Chorny, I., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421779112 · Cited by 254
A strategy for risk mitigation of antibodies with fast clearance
Hötzel, I., Theil, F.-P., Bernstein, L. J., Prabhu, S., Deng, R., Quintana, L., Lutman, J., Sibia, R., Chan, P., Bumbaca, D., et al. (2012) · mAbs · doi:10.4161/mabs.22189 · Cited by 245
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Mousa, J. J., Kose, N., Matta, P., Gilchuk, P., & Crowe, J. E. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.271 · Cited by 111
(2018) · doi:10.1080/19420862.2017.1389355 · Cited by 80
Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV
Skaricic, D., Traube, C., De, B., Joh, J., Boyer, J., Crystal, R. G., & Worgall, S. (2008) · Virology · doi:10.1016/j.virol.2008.04.016 · Cited by 54
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
Dostalek, M., Prueksaritanont, T., & Kelley, R. F. (2017) · mAbs · doi:10.1080/19420862.2017.1323160 · Cited by 45
Li, B., Fouts, A. E., Stengel, K., Luan, P., Dillon, M., Liang, W.-C., Feierbach, B., Kelley, R. F., & Hötzel, I. (2014) · mAbs · doi:10.4161/mabs.27875 · Cited by 28
“This is particularly relevant for therapeutic antibodies as non-specific binding can potentially lead to faster than expected clearance and reduced in vivo potency.(9) We tested five double mutants and the single-site T55R mutant for potential off-target binding using a baculovirus (BV) particle non-specific ELISA tha…”
BackgroundIn vitro affinity maturation of antibody against membrane-bound GPCR molecules
Wang, J., An, L., Zhao, Y., Zhang, C., Li, S., Ye, C., Jing, S., & Hang, H. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10030-x · Cited by 11
Metadata
- Authors
- Wu, H., Pfarr, D. S., Johnson, S., Brewah, Y. A., Woods, R. M., Patel, N. K., White, W. I., Young, J. F., & Kiener, P. A.
- Venue
- Journal of Molecular Biology
- Publisher
- Elsevier BV
- Published
- 2007-05
- Volume
- 368
- Issue
- 3
- Pages
- 652-665
- ISSN
- 0022-2836 (ISSN-L)
- OpenAlex
- W2093529351
- Cited by
- 373
- References
- 23
- FWCI
- 17.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.